Disease · HP_0001298
Encephalopathy
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Encephalopathy. Diseases, record HP_0001298. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001298
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Encephalopathy
- Open Targets ID
- HP_0001298
- Highest stage of its drugs
- Approval, for 2 of its 26 drugs, from DailyMed
Source Open Targets
Drugs26
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LEVOCARNITINE | CHEMBL1149 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| THIAMINE | CHEMBL1588 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| RIFAXIMIN | CHEMBL1617 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| LACTULOSE | CHEMBL296306 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| ORNITHINE | CHEMBL446143 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| LEVETIRACETAM | CHEMBL1286 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MAGNESIUM SULFATE | CHEMBL3989857 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NIFUROXAZIDE | CHEMBL244888 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BQ 788 | CHEMBL1741040 | Small molecule | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
| SATRALIZUMAB | CHEMBL3833307 | Antibody | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
1 to 10 of 26
See all 26 drugsTargets16
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRA1A | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRB1 | Adrenergic receptor beta | 1 | Adrenergic receptor beta antagonist | Unknown | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor beta | 1 | Adrenergic receptor beta antagonist | Unknown | https://conductscience.org/library/genes/154 | Drugs and targets |
| ADRB3 | Adrenergic receptor beta | 1 | Adrenergic receptor beta antagonist | Unknown | https://conductscience.org/library/genes/155 | Drugs and targets |
| CACNA1B | Voltage-dependent N-type calcium channel subunit alpha-1B | 1 | Voltage-gated N-type calcium channel alpha-1B subunit blocker | Phase 3 | https://conductscience.org/library/genes/774 | Drugs and targets |
| CD19 | B-lymphocyte antigen CD19 | 1 | B-lymphocyte antigen CD19 binding agent | Phase 2 | https://conductscience.org/library/genes/930 | Drugs and targets |
| EPOR | Erythropoietin receptor | 1 | Erythropoietin receptor agonist | Phase 2 | https://conductscience.org/library/genes/2057 | Drugs and targets |
| HCN4 | Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 | 1 | Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker | Unknown | https://conductscience.org/library/genes/10021 | Drugs and targets |
1 to 10 of 16
See all 16 targetsTrials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00686920 | Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy | Phase 3 | 322 | 2019-08-14 | Hepatic Encephalopathy | RIFAXIMIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01966419 | Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE) | Phase 2 | 231 | 2021-09-16 | Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy | ORNITHINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03921554 | JAK Inhibitor Treatment in AGS | Phase 2 | 54 | 2025-02-12 | Aicardi Goutieres Syndrome | BARICITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00811434 | Study of Lactulose in Children With Chronic Liver Disease | Phase 2 | 16 | 2014-02-10 | Minimal Hepatic Encephalopathy | LACTULOSE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00364689 | RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial | Phase 3 | 13 | 2019-09-17 | Hepatic Encephalopathy | LACTULOSE, RIFAXIMIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00597909 | Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy | Phase 2 | 1 | 2016-03-31 | Hepatic Encephalopathy | SODIUM BENZOATE, SODIUM PHENYLACETATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT06851078 | Evaluation of Early Administration of Levetiracetam in the Prevention and Treatment Encephalopathy in Septic Shock: Randomized, Double-blind, Placebo-controlled Trial | Phase 3 | 280 | Septic Shock | LEVETIRACETAM | Its record names the disease | ClinicalTrials.gov | |
| NCT02294292 | Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its Impact on Morbidity and Mortality | Not applicable | 189 | Diastolic Dysfunction, Chronic Liver Disease | CARVEDILOL, IVABRADINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04432662 | Darbepoetin in Neonatal Encephalopathy Trial | Phase 2 | 150 | Neonatal Encephalopathy | DARBEPOETIN ALFA | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05786859 | The Efficacy and Safety of Rifaximin Treatment | Early phase 1 | 124 | Liver Failure, Acute on Chronic, Hepatic Encephalopathy, HBV, Hepatitis B, Rifaximin, Effect of Drug | RIFAXIMIN | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| New Rifaximin vs Continuing Rifaximin: Number Of Participants With A Significant Mean Change From Baseline In Vital Signs | 0 of 252 | 0 of 70 | 322 | NCT00686920 | Trial comparisons |
| New Rifaximin vs Continuing Rifaximin: serious adverse events | 158 of 252 | 49 of 70 | 322 | NCT00686920 | Trial comparisons |
| Ornithine Phenylacetate vs Placebo: deaths from any cause | 11 of 114 | 15 of 112 | 226 | NCT01966419 | Trial comparisons |
| Ornithine Phenylacetate vs Placebo: serious adverse events | 29 of 114 | 34 of 112 | 226 | NCT01966419 | Trial comparisons |
| Lactulose vs Placebo: serious adverse events | 0 of 12 | 0 of 9 | 21 | NCT00811434 | Trial comparisons |
Papers from its trials31
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001298
GET https://conductscience.org/api/diseases/v1/HP_0001298/drugs?page=2